Study guide
3.2 Acute Cardiogenic Pulmonary Edema
AACN Cardiac Medicine Certification CMC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview and the CMC Test Plan
1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them
2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease
2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy
3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease
3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup
4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions
4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation
5 Chapter 5: Vascular Conditions and Vascular Interventions
5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications
6 Chapter 6: Shock States and Mechanical Circulatory Support
6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD
7 Chapter 7: Cardiac Procedures and Structural Heart Interventions
7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications
8 Chapter 8: Cardiovascular Pharmacology
8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure
9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary
9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients
10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral
10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients
11 Chapter 11: Monitoring and Diagnostics
11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography
12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions
12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease
3.2 Acute Cardiogenic Pulmonary Edema
Key Takeaways Explain This Topic AI
Interstitial edema begins once pulmonary artery occlusion pressure exceeds 18-20 mmHg; frank alveolar flooding generally requires a PAOP above 25 mmHg, and chronic heart failure patients tolerate higher pressures because lymphatic clearance capacity expands up to tenfold.
In SCAPE (sympathetic crashing acute pulmonary edema) the patient is wet in the lungs and dry in the tank: non-invasive ventilation plus high-dose nitroglycerin (400-1,000 mcg bolus, then 100-400 mcg/min) comes before loop diuretics, which acutely activate the renin-angiotensin-aldosterone system.
Loop diuretic dosing follows home dose: an IV dose of 1 to 2.5 times the total daily oral dose, with bumetanide 1 mg IV equal to furosemide 40 mg IV and torsemide 20 mg IV.
An edema fluid to plasma protein ratio under 0.65 with a bat-wing perihilar pattern and Kerley B lines points to cardiogenic edema; a ratio above 0.75 with peripheral patchy infiltrates and a normal cardiac silhouette points to ARDS.
Hold nitroglycerin for phosphodiesterase-5 inhibitor use within 24 hours (sildenafil, vardenafil) or 48 hours (tadalafil), right ventricular infarction, severe aortic stenosis, or hypotension.
Last updated: August 2026
Why Pulmonary Edema Sits at the Center of the Cardiovascular Domain
Acute cardiogenic pulmonary edema (ACPE) is the final common pathway of almost every condition in Domain I of the CMC test plan. Ischemia, acute valvular failure, hypertensive crisis, tachyarrhythmia and decompensated cardiomyopathy all end the same way: fluid in the alveolus. CMC items rarely ask you to name the syndrome. They hand you a hypertensive, diaphoretic, hypoxemic patient and ask what the nurse does first , or which single finding separates a cardiac cause from acute respiratory distress syndrome. Getting the phenotype right in the first ten minutes determines which drug you reach for, and reaching for the wrong one is the classic distractor.
Starling Forces and the Pressure Thresholds
Fluid movement across the pulmonary capillary is governed by the Starling equation : net filtration equals the filtration coefficient multiplied by the hydrostatic gradient (capillary minus interstitial pressure) minus the oncotic gradient (capillary minus interstitial oncotic pressure, scaled by the reflection coefficient). In a healthy adult lung, pulmonary capillary hydrostatic pressure is 8-12 mmHg while plasma colloid oncotic pressure is 25-28 mmHg, so the net gradient keeps the alveolus dry and the small volume that does leak is cleared by pulmonary lymphatics.
Raise the hydrostatic side and the balance tips in a predictable, testable sequence. Pulmonary artery occlusion pressure (PAOP) — also called pulmonary capillary wedge pressure — is the bedside surrogate for left atrial and pulmonary capillary pressure.
- PAOP What is happening Bedside correlate
- 8-12 mmHg Normal; lymphatics clear filtrate easily Clear lungs
- 13-18 mmHg Increased filtration, still compensated; lymph flow rises up to tenfold Exertional dyspnea only
>18-20 mmHg Interstitial edema begins Orthopnea, peribronchial cuffing and Kerley B lines on film, hypoxemia from V/Q mismatch
>25 mmHg Frank alveolar flooding Crackles, pink frothy sputum, shunt physiology, refractory hypoxemia
Two modifiers matter clinically and appear in stems. First, chronic left-sided pressure elevation expands lymphatic drainage capacity, so a patient with long-standing heart failure may be walking around at a PAOP of 28-30 mmHg without alveolar flooding, while a previously normal heart floods at 20. Second, hypoalbuminemia lowers the oncotic barrier: with an albumin under 2 g/dL the same patient floods at a PAOP well below 18 mmHg.
Flash Pulmonary Edema and Its Precipitants
Flash pulmonary edema is ACPE that develops over minutes to a couple of hours and is driven by afterload and fluid redistribution from the splanchnic and venous reservoirs into the pulmonary circuit rather than by accumulated total body volume. The tell is a patient who is drowning but whose weight is unchanged from the clinic visit two weeks ago and who has no peripheral edema. Classic precipitants:
Hypertensive emergency with an intense catecholamine surge - the SCAPE presentation described below.
Bilateral renal artery stenosis (Pickering syndrome) - recurrent unexplained flash edema, often with preserved ejection fraction and a creatinine that jumps when an ACE inhibitor or ARB is started.
Acute severe mitral regurgitation from papillary muscle rupture, typically 2-7 days after an inferior myocardial infarction, because the posteromedial papillary muscle has a single blood supply from the posterior descending artery. The murmur is often soft or absent because the pressure gradient equalizes fast; look instead for a giant v wave on the PAOP tracing.
Acute severe aortic regurgitation from type A dissection or endocarditis - short soft diastolic murmur, narrow pulse pressure rather than wide, premature mitral valve closure on echo.
New atrial fibrillation with rapid ventricular response or any tachyarrhythmia - loss of atrial kick plus shortened diastolic filling in a stiff ventricle.
Severe aortic stenosis , hypertrophic obstructive cardiomyopathy, or prosthetic valve thrombosis.
Transient ischemia producing acute diastolic dysfunction.
Nonadherence and iatrogenesis - missed diuretic doses, missed dialysis, a high-sodium meal, NSAIDs, thiazolidinediones, corticosteroids, or a large IV contrast or fluid load.
The Presentation and the Cardiac Asthma Trap
The patient is sitting bolt upright or tripoding, respiratory rate above 30, oxygen saturation under 90% on room air, skin cool, gray and drenched with sweat from sympathetic vasoconstriction, agitated and unable to speak in full sentences. Crackles begin at the bases and ascend; pink frothy sputum is a late sign. An S3 gallop and jugular venous distension support the cardiac origin. Roughly half of ACPE presentations occur with preserved ejection fraction, so a normal echo report from last year does not exclude it.
The trap is cardiac asthma : bronchial wall edema produces true wheezing, and the patient gets nebulized beta agonists and steroids for a presumed COPD exacerbation while the real problem is a wedge pressure of 30. A hypertensive, diaphoretic patient with new wheeze and an S3 has heart failure until proven otherwise, and beta agonists in that setting add tachycardia, hypokalemia and myocardial oxygen demand.